Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bempegaldesleukin, pembrolizumab, and radiation in HNSCC
NCT04936841Phase 2Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- Aug 2021
- Primary completion
- Oct 2022
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of bempegaldesleukin in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Wisconsin–Madison. Started Aug 2021; status: terminated.
02
Drugs
bempegaldesleukin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04936841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04936841.